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ABSTRACT 39 
Reasons for performing the study: Synthetic glucocorticoids are used to treat inflammatory 40 
conditions in horses. In other pregnant animals, glucocorticoids are given to stimulate fetal 41 
maturation with long-term metabolic consequences for the offspring if given pre-term. 42 
However, their metabolic effects during equine pregnancy remain unknown. 43 
Objective: Thus, this study investigated the metabolic effects of dexamethasone 44 
administration on pregnant pony mares and their foals after birth. 45 
Study Design: Pancreatic β cell function was measured in pregnant pony mares and their 46 
foals following maternal administration of dexamethasone or saline in late gestation.  47 
Methods: Three doses of dexamethasone (200 µg/kg im) were given to 6 pony mares at 48h 48 
intervals beginning at ≈ 270 days of pregnancy. Control saline injections were given to 5 49 
mares using the same protocol. After fasting overnight, pancreatic β cell responses to 50 
exogenous glucose were measured in the mares before, during and after treatment. After 51 
birth, pancreatic β cell responses to exogenous glucose and arginine were measured in the 52 
foals at 2 and 12 weeks.  53 
Results: In mares during treatment, dexamethasone but not saline increased basal insulin 54 
concentrations and prolonged the insulin response to exogenous glucose. Basal insulin and 55 
glucose concentrations still differed significantly between the two groups 72h post-treatment. 56 
Dexamethasone treatment significantly reduced placental area but had little effect on foal 57 
biometry at birth or subsequently. Foal β cell function at 2 weeks was unaffected by maternal 58 
treatment. However, by 12 weeks, pancreatic β cell sensitivity to arginine, but not glucose, 59 
was less in foals delivered by dexamethasone than saline treated mares.  60 
Conclusions: Dexamethasone administration induced changes in maternal insulin-glucose 61 
dynamics, indicative of insulin resistance, and had subtle longer term effects on postnatal β 62 
cell function of the foals. The programming effects of dexamethasone in horses may be 63 
mediated partially by altered maternal metabolism and placental growth.  64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
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INTRODUCTION 73 
 74 
In several species, synthetic glucocorticoids like dexamethasone are administered clinically 75 
for a range of conditions, often with an inflammatory component. In horses, the anti-76 
inflammatory properties of these drugs are used to treat joint and respiratory problems as well 77 
as endometritis, allergic reactions and endotoxic shock [1-4]. They have also been given to 78 
regulate ovarian function in non-pregnant mares [3-5].  In humans, synthetic glucocorticoids 79 
are used to treat a similar range of inflammatory diseases, but they are also given routinely to 80 
healthy pregnant women threatened with preterm delivery to improve neonatal viability of 81 
their infants [6]. During pregnancy, these drugs mimic the normal rise in endogenous 82 
glucocorticoids seen in fetuses near term, which promotes maturation of fetal tissues and, in 83 
some species, also triggers labour [7]. Synthetic glucocorticoids are, therefore, used to induce 84 
delivery in cattle and sheep at or near term [8].  In mares, synthetic glucocorticoids appear to 85 
be less effective at inducing delivery in late gestation and can be detrimental to pregnancy 86 
outcome if given too close to full term [9, 10]. However, early delivery of viable foals has 87 
been observed in response to maternal dexamethasone administration between 315 and 322 88 
days of gestation [11-13]. 89 
 90 
In healthy non-pregnant animals, administration of synthetic glucocorticoids at the anti-91 
inflammatory doses has a number of side effects including metabolic actions that leads to 92 
hyperglycaemia, insulin resistance and to type 2 diabetes if given in excess [14,15]. In non-93 
pregnant horses, dexamethasone causes rapid changes in glucose-insulin dynamics and 94 
insulin resistance, which can persist for several days after cessation of treatment [16-20]. 95 
Synthetic glucocorticoids are also thought to increase the risk of laminitis, particularly in 96 
horses prone to the disease [21]. In comparison, relatively little is known about the maternal 97 
metabolic outcomes of dexamethasone treatment in pregnant animals, although pregnancy is 98 
associated with a natural state of insulin resistance in many species including the horse [22-99 
24].  Indeed, there are many more studies of the metabolic consequences of this treatment for 100 
the postnatal offspring than for the pregnant mother per se [25-27]. Studies in pregnant rats, 101 
guinea pigs, sheep and non-human primates have shown that maternal administration of 102 
synthetic glucocorticoids during late pregnancy alters fetal development and induces 103 
postnatal abnormalities in cardiovascular, metabolic and endocrine function in the offspring 104 
[7, 24-26]. In particular, there are changes in glucose metabolism in the adult offspring, 105 
which are due, in part, to altered secretion and action of insulin [25-27].  However, nothing is 106 
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known about the metabolic consequences of dexamethasone treatment of pregnant horses 107 
either for the mare or her foal after birth, although there are changes in maternal progestagen 108 
concentrations and adreno-cortical function of the newborn foal after dexamethasone 109 
administration to pregnant mares near term [13]. This study, therefore, examined pancreatic β 110 
cell function in pregnant mares and their foals after birth following dexamethasone 111 
administration in late gestation.  Postnatally, pancreatic β cell function was tested using both 112 
glucose and arginine, as they act through different mechanisms to secret insulin and are 113 
known to be effective in both fetal and newborn foals [28-30]. 114 
 115 
 116 
METHODS 117 
 118 
Animals 119 
A total of 11 pregnant pony mares of known gestational age were used. They were housed in 120 
individual stables and fed hay ad libitum and concentrates twice a day (Dodson and Horrell a 121 
Mare and young stock mix, 1 kg/100kg 12.5 MJ/kg, 14% Crude protein, 4,5% Oils, 8% 122 
Crude fibre). All mares delivered spontaneously without assistance. On the day of birth the 123 
foals were treated with equine tetanus antitoxin (1000IU, Intervet Ltd. UK) and remained 124 
with their mothers throughout the experimental period. One foal from a control mare had 125 
limb deformities and was euthanised at 48h on veterinary advice. At the end of the entire 126 
study, the animals were either rehomed (n=9 mares, n=5 foals) or euthanized (n=2 mares, n=5 127 
foals; 200 mg/kg of sodium pentobarbitoneb) to provide tissue for other research studies. All 128 
studies were carried out under the UK Animal (Scientific Procedures) Act 1986 after 129 
permission from the Animal Welfare and Ethical Review Board of the University of 130 
Cambridge. 131 
 132 
Experimental procedures 133 
Mares: The mares were assigned randomly to be treated intramuscularly with either 134 
dexamethasone (200 µg/kg i.m, Dexamethasone 21-phosphatec in 0.9% w/v saline, n=6) or 135 
the equivalent volume of saline as a control (0.9% w/v, n=5) on three occasions at 48 h 136 
intervals beginning at a mean gestational age of 267.0 ± 12.0 days that was similar in the two 137 
treatment groups (Saline, 271.0 ± 19.0 days; n=5: Dexamethasone, 263.0 ± 16.0 days; n=6; 138 
P>0.05, Term ~335 days). The two groups were of similar bodyweight at the onset of 139 
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treatment (Saline, 273.0 ± 19.0 kg; n=5: Dexamethasone, 251.0 ± 6.5 kg; n=6; P>0.05). Four 140 
days before injections began, a long stay catheter (16 gauged) with an extension tube was 141 
inserted into a jugular vein under local anaesthesia (Intra-Epicanee).  Between 08.00-08.30 h 142 
daily, the jugular catheter was flushed with heparinised saline to maintain patency. An 143 
intravenous glucose tolerance test was carried out 48 h before treatment began (pre-144 
treatment), then, again 24 h after the second injection (during treatment) and, finally, 72 h 145 
after the third injection of saline or dexamethasone (post-treatment). In each test, blood 146 
samples (10 ml) were taken at 30, 15 and 0 min before and at 5, 15, 30, 45, 60, 90 and 120 147 
min after intravenous administration of glucose (0.5 g/kg, Dextrose, 40% w/vf) for the 148 
measurement of plasma glucose and insulin at all times and plasma L-lactate at 0 min. After 149 
glucose administration, the catheter was flushed with 20 ml of saline (0.9% w/v). Mares were 150 
without food overnight before the glucose tolerance test and did not receive their morning 151 
ration of concentrates until after the glucose tolerance test was complete. Water was freely 152 
available at all times. At the end of the experimental period, the catheter was removed and the 153 
mares were monitored twice daily for signs of impending delivery. 154 
 155 
Foals:  At birth, the foal and placenta were weighed and measured.  Placental area was 156 
measured by laying the placenta on a plastic sheet, cutting around the area and weighing the 157 
resulting template. Using the weight of a known area of the plastic sheeting, the total 158 
placental area was calculated. After birth, the foals were weighed and measured weekly until 159 
12 weeks. Blood samples (5 ml) were taken by venipuncture from the jugular vein of all foals 160 
on the day of birth (Day 1) for measurement of plasma cortisol concentrations. At 10-12 days 161 
of postnatal age, the jugular vein was catheterized as described for the mares.  Beginning at 2 162 
weeks, glucose (0.5 g/kg, Dextrose, 40% w/vf,) followed by arginine (100 mg/kgg) were 163 
given intravenously over 5 min at a 48-72 h interval at doses known to be effective at 164 
stimulating insulin secretion in newborn foals [29]. On each occasion, the catheter was 165 
flushed with with saline (10 ml, 0.9% w/v). Blood samples (5 ml) were taken from the 166 
jugular catheter at 30, 15 and 0 min before and at 5, 15, 30, 45, 60, 90 and 120 min after 167 
substance administration. At 2 weeks, foals remained with their mothers throughout the 168 
experiments but were muzzled to prevent suckling from 1 h before sampling began until the 169 
end of the sampling period. At the end of this series of experiments, the jugular catheter was 170 
removed and the foal was re-catheterised at ≈ 12 weeks.  The pancreatic β cell challenges 171 
were then repeated in the same order using the same protocol as at 2 weeks.  To minimize 172 
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stress, the older foals were not muzzled but were separated from their mothers by a barrier 173 
which allowed sight and interaction but no suckling for 3 h before sampling began until the 174 
end of the sampling period.  175 
 176 
Biochemical analyses 177 
 178 
Blood samples were added to tubes containing either heparin or EDTA and centrifuged 179 
immediately. The plasma was stored at -20 ºC until analysis of plasma metabolite and 180 
hormone concentrations. Plasma glucose and lactate concentrations were measured using a 181 
glucose-lactate analyserh. Plasma α–amino nitrogen concentrations were determined on 182 
deproteinised plasma by the colourimetric method of Evan et al. [31] using glycine as a 183 
standard as an index of the arginine concentrations. Plasma insulin concentration was 184 
measured by an ELISA assayi validated for use with equine plasma [32]. The intra- and inter-185 
assay coefficients of variation for the insulin assay were 3.4% and 13% respectively.  Plasma 186 
cortisol was assessed using an ELISAj validated for equine plasma as described previously 187 
[33]. The intra- and inter-assay coefficients of variation for this assay were 4.3% and 8.9% 188 
respectively.   189 
 190 
Statistical analyses 191 
All values are expressed as means (±SEM). Statistical comparisons between groups were 192 
made using Student’s t-test, or one-way or two-way ANOVA with repeated measures (time) 193 
followed by Turkey post hoc test, as appropriate. When time or treatment was identified as 194 
significant factors by two-ANOVA, the two treatment groups were analysed separately by 195 
one way ANOVA. The responses to glucose and arginine administration were measured as 196 
delta concentrations from baseline values at 0 min. Insulin data was normalized by log 197 
transformation, where required. For each challenge, the area under the curve (AUC) for the 198 
glucose (AUCG), α-amino nitrogen (AUCAN) and insulin (AUCI) responses was calculated 199 
as the integrated plasma concentration after administration of glucose or arginine from 0-120 200 
min above the baseline concentration at 0 min for all positive values. The area above the 201 
curve (AAC) for the hypoglycaemic response to insulin was calculated in the same way. All 202 
statistical analyses were performed using Sigma-Statk and considered significant when 203 
P<0.05. 204 
 205 
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RESULTS 206 
 207 
Effects of dexamethasone treatment on the pregnant mares. 208 
 209 
Basal insulin and metabolite concentrations 210 
Plasma concentrations of glucose, lactate and insulin after an overnight fast did not differ 211 
between the two groups of mares before treatment began (Table 1). However, 3 days after 212 
beginning treatment, fasted concentrations of plasma glucose, lactate and insulin were 213 
significantly higher in dexamethasone than saline treated animals (Table 1).  Three days after 214 
finishing dexamethasone treatment, fasting concentrations of lactate and insulin were not 215 
significantly different from the pre-treatment values (Table 1). However, post-treatment 216 
fasting levels of insulin were higher in dexamethasone- than saline-treated mares (Table 1). 217 
In contrast, fasting concentrations of plasma glucose in dexamethasone-treated mares post-218 
treatment were lower than both their own pre-treatment values and the post-treatment 219 
concentrations in saline-treated mares (Table 1). There were no changes in the fasting 220 
concentrations of glucose, lactate or insulin in mares receiving saline with time over the 221 
treatment period (Table 1).  222 
 223 
Pancreatic β response to glucose  224 
The increment and maximal concentration of plasma glucose after glucose administration did 225 
not differ significantly with time over the treatment period in either group of mares or 226 
between the two groups of mares at any time over the treatment period (Figure 1A, Table 1). 227 
The AUCG were also unaffected by treatment (Figure 2A).  In common with previous 228 
findings [23], the insulin response to glucose administration varied widely between pregnant 229 
mares, even pre-treatment (Figure 2B).  Pre-treatment, there were no significant differences 230 
in the insulin increment, maximal insulin concentration or time course of the insulin response 231 
to glucose between saline- and dexamethasone-treated mares (Table 1, Figure 1B).  However, 232 
during dexamethasone treatment, the insulin response to glucose was more prolonged than 233 
seen in mares receiving saline (Figure 1B). The maximum increment and the maximal 234 
concentrations of plasma insulin were also greater in the dexamethasone than saline group of 235 
mares during treatment (Table 1). In the dexamethasone- but not the saline-treated mares, the 236 
area under the insulin curve (AUCI) during treatment was greater than their respective pre-237 
treatment values (Figure 2B).  Relative insulin secretion, measured as the ratio of the AUCI 238 
to AUCG, showed the same profile with treatment as the AUCI (Figure 2C). 239 
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 240 
Delivery  241 
Mares delivered uneventfully at a mean gestational age of 335.0 ± 2.9 days (Saline, 338.0 ± 242 
0.9 days; n=5, 2 male & 3 female foals: Dexamethasone, 333.0 ± 5.3 days; n=6, 3 males 3 243 
females, P>0.05).  At delivery, placental weight was similar while gross placental area was 244 
significantly less in dexamethasone- than saline-treated mares (Table 2).  245 
 246 
 247 
Effects of dexamethasone treatment on the foals  248 
 249 
Biometry  250 
All foals stood and suckled within 1h of delivery, and were classified as mature by clinical 251 
criteria [34].  On the day of delivery, plasma cortisol concentrations were similar in foals 252 
delivered by dexamethasone (22.3 ± 2.7 ng/ml, n = 6) and saline treated mares (21.8 ± 4.0 253 
ng/ml, n = 5, P>0.05). At birth, foals of dexamethasone-treated mares tended to be smaller 254 
than those of saline treated mares but there were no statistically significant differences in 255 
body weight, crown rump length or height at the withers between the two groups of newborn 256 
foals (P=0.07, all cases, Table 2). Only femur length of the newborn foals was significantly 257 
shorter after maternal dexamethasone treatment (Table 2).  Birth weight per cm2 of placenta 258 
was unaffected by maternal treatment (Saline, 3.26 ± 0.18 g/cm2, n = 5; Dexamethasone, 3.13 259 
± 0.20 g/cm2, n = 6, P>0.05). None of the morphometric measurements of the foals differed 260 
significantly between the two treatment groups at either 2 or 12 weeks (Table 2). There were 261 
also no differences in the growth rate or fractional growth rate of any of the body 262 
measurements of the foals between the two treatment groups over the first 12 weeks after 263 
birth (P>0.05, data not shown). In addition, there were no differences in the plasma cortisol 264 
concentrations between the two treatment groups at 2 or 12 weeks (2 weeks; Saline, 40.5 ± 265 
4.8 ng/ml, n = 4; Dexamethasone, 40.3 ± 6.2 ng/ml, n = 6: 12 weeks; Saline 27.5 ± 2.6 ng/ml, 266 
n = 4; Dexamethasone, 35.0 ±3.4 ng/ml, n = 6, P>0.05 both ages)  267 
 268 
 269 
 270 
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Pancreatic β cell responses 271 
Glucose: At 2 and 12 weeks, there were no significant differences in the basal concentrations 272 
of plasma glucose, α-amino nitrogen or insulin before administration of glucose or arginine 273 
between the two treatment groups (Table 3).  At both ages, there were also no significant 274 
differences in the incremental or maximal concentrations of glucose or insulin in response to 275 
glucose administration between the two treatment groups (Figure 3A & B, Table 3).  276 
However, the maximal increment and the maximum concentration of plasma glucose and the 277 
AUCG were greater at 12 weeks than 2 weeks, irrespective of maternal treatment (Figure 3A, 278 
Table 3). The insulin response to glucose administration was also more prolonged at 12 than 279 
2 weeks in both treatment groups (Fig 3B). However, there were no significant differences in 280 
AUCI or relative insulin secretion in the foals with either maternal treatment or increasing 281 
age (Table 3).  282 
 283 
Arginine: The incremental and maximal concentration of plasma α-amino nitrogen in 284 
response to arginine administration in the foals was unaffected by maternal treatment at 2 285 
weeks (Figure 3C, Table 3). The incremental and maximal concentrations of insulin and the 286 
AUCI in response to arginine were unaffected by maternal treatment at this age (Figure 3D, 287 
Table 3).  However, at 12 weeks, the increment in plasma α-amino nitrogen concentration 288 
was more prolonged and significantly greater in foals of dexamethasone treated mares 289 
(Figure 3C).  Consequently, relative to controls receiving saline, the AUCAN was 290 
significantly greater in 12 week old foals of dexamethasone- than saline-treated mares 291 
(Figure 3D, Table 3).  The increment in insulin concentration was less in the dexamethasone 292 
than saline group of 12 week old foals at 5 min after arginine administration although not at 293 
the later sampling times (Figure 3D). As a result, relative insulin secretion, the ratio of AUCI 294 
to AUCAN, was significantly less in the dexamethasone than saline group of foals at 12 295 
weeks but not at 2 weeks of postnatal age (Table 3). At 12 weeks, the insulin response to 296 
arginine administration was more prolonged than in the younger foals, irrespective of 297 
maternal treatment (Figure 3D).   298 
 299 
 300 
 301 
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DISCUSSION 302 
The study shows for the first time that treatment of pregnant pony mares at ≈ 270 days of 303 
gestation with the synthetic glucocorticoid, dexamethasone, induces transient maternal 304 
hyperinsulinaemia, indicative of increased insulin resistance. During treatment, basal fasting 305 
concentrations of plasma insulin and the increment in plasma insulin in response to 306 
exogenous glucose were significantly greater in dexamethasone-treated mares than in control 307 
mares receiving saline. The maternal AUCI was also significantly greater during treatment 308 
with dexamethasone but not saline. Maternal dexamethasone treatment had no effect on the 309 
length of gestation but reduced gross placental area at delivery. Despite these changes, 310 
dexamethasone treatment of pregnant mares had relatively little effect on their offspring with 311 
only subtle changes in pancreatic β cell function in their 12 week old foals.  312 
 313 
Maternal effects 314 
Several previous studies have shown that dexamethasone at doses similar to those used here 315 
induces hyperglycaemia, hyperinsulinaemia and insulin resistance in non-pregnant horses 316 
[16-20].  These changes are seen in response to single and multiple doses of dexamethasone 317 
and begin within 2 h of administration with recovery taking up to 2 week after multiple 318 
dosing [1, 16, 18, 19]. Similar increases in peripheral insulin resistance are seen in non-319 
pregnant horses with hyperadrenocorticism induced by pars intermedia dysfunction [35]. In 320 
the current study, dexamethasone treatment of pregnant mares caused fasting 321 
hyperinsulinaemia, lactacidaemia and an enhanced pancreatic β cell response to exogenous 322 
glucose without any changes in glucose dynamics or fasting hyperglycaemia.  At this stage of 323 
pregnancy, mares are already insulin resistant and have a significant feto-placental glucose 324 
requirement [22, 24, 36].  Dexamethasone treatment, therefore, appears to further increase 325 
maternal insulin resistance without the concomitant changes in glycaemia observed in non-326 
pregnant horses. This suggests that, during dexamethasone treatment, any reduction in 327 
glucose uptake by insulin resistant maternal tissues is balanced by an increase in glucose 328 
transfer to the rapidly growing fetus that is insulin independent [36]. Maternal 329 
hyperinsulinaemia and insulin resistance together with elevated whole body glucose disposal 330 
have been seen in pregnant rats treated with dexamethasone in late gestation when glucose 331 
demands of the gravid uterus are high [37]. Increased lactate production has also been 332 
observed previously in response dexamethasone treatment in human and other species [38, 333 
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39]. In the current study, the insulin-glucose dynamics of the dexamethasone-treated mares 334 
were still abnormal 72 h after ceasing treatment with significant differences in basal fasting 335 
concentrations of both insulin and glucose between the two treatment groups at this time. 336 
Indeed, in dexamethasone-treated mares, fasting glucose concentrations were lower post-337 
treatment than pre-treatment, although post-treatment insulin concentrations were not 338 
significantly different from the pre-treatment values. Since dexamethasone would have 339 
cleared from the maternal circulation by 72 h post-treatment [18], these findings indicate that 340 
insulin sensitivity of the dexamethasone-treated mares may have been greater post- than pre-341 
treatment, consistent with previous findings in non-pregnant horses receiving dexamethasone 342 
[17, 20].  343 
 344 
Foal effects 345 
In the current study, dexamethasone treatment had little apparent effect on gestational length 346 
or prepartum maturation as all foals were mature at birth, and stood and sucked within the 347 
normal time, irrespective of maternal treatment [34].  At delivery, placental area was smaller 348 
after maternal dexamethasone treatment, consistent with the known growth inhibitory effects 349 
of synthetic glucocorticoids on the placenta in other species [26, 40].  This led to a tendency 350 
for smaller foals after maternal dexamethasone treatment but only femur length was reduced 351 
significantly at birth. In previous studies of dexamethasone administration, foal birth weight 352 
was also unaffected, although crown rump length was reduced at dexamethasone doses 353 
similar to those used here [11-13].  In other species, maternal administration of synthetic 354 
glucocorticoids at a similar dose and stage of gestation reduces fetal weight and results in 355 
lower birth weight [7, 25-27].  Collectively, these observations suggest that dexamethasone 356 
can restrict fetal bone growth but may be less effective at inhibiting growth of fetal somatic 357 
tissues in horses than other species.  358 
 359 
Maternal dexamethasone treatment had little effect on pancreatic β cell sensitivity to glucose 360 
of the foals 2 and 12 weeks after birth. The insulin responses of the foals to glucose were 361 
similar in the two treatment groups at both ages and resembled those published previously for 362 
age-matched foals of mares receiving no treatment [41]. In other species, maternal 363 
dexamethasone treatment during late pregnancy alters glucose-stimulated insulin secretion in 364 
11 
 
the offspring, although at older postnatal ages than studied here [25-27]. However, there were 365 
developmental changes in equine β cell responses to glucose over the first 12 week of 366 
postnatal life, irrespective of maternal treatment. Insulin secretion in response to exogenous 367 
glucose switched from a monophasic response at 2 weeks to a more biphasic pattern of 368 
response at 12 weeks, without any significant age-related change in AUCI. This resembled 369 
the developmental profile of glucose-stimulated insulin secretion seen previously in foals of 370 
untreated mares [41]. Since the AUCG was significantly greater at 12 weeks than 2 weeks of 371 
age, the current findings suggest that insulin sensitivity decreases with age over the first 12 372 
weeks of postnatal life, irrespective of maternal treatment, in keeping with previous findings 373 
in older untreated foals [42]. 374 
 375 
In contrast to β cell glucose sensitivity, the insulin response to arginine was affected by 376 
maternal dexamethasone treatment by the time the foals were 12 weeks old. The increments 377 
in α-amino-nitrogen and AUCAN were greater and the initial insulin increment and relative 378 
insulin secretion were less in the dexamethasone- than saline-treated group of 12 week old 379 
foals. Collectively, these findings suggests that arginine may be less effective at stimulating 380 
insulin release and that insulin may be less effective at stimulating tissue amino acid uptake 381 
in 12 week old foals after maternal dexamethasone treatment. Arginine depolarises β cells 382 
directly through ATP-dependent K+ channels whereas glucose acts indirectly on these 383 
channels via generation of ATP [28]. In fetal horses, the pancreatic β cell response to glucose 384 
but not arginine increases near term indicating that there is prepartum maturation of the 385 
insulin secretory pathways upstream of β cell depolarization [30]. The current findings 386 
suggests that maturation of the insulin secretory pathway continues after birth and is 387 
influenced by maternal dexamethasone treatment, particularly at and/or downstream of the 388 
depolarising K+ channels.  However, further studies are required to establish the extent to 389 
which these changes in β cell sensitivity to arginine are due directly to dexamethasone 390 
exposure in utero or indirectly to the maternal metabolic and other physiological alterations 391 
that affect perinatal development of the foal. Certainly, maternal glucocorticoid overexposure 392 
in late pregnancy is known to influence mammary development and milk quality in the mare 393 
[13]. 394 
 395 
 396 
 397 
 398 
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CONCLUSIONS 399 
Maternal dexamethasone treatment has metabolic actions in the mare during late pregnancy 400 
but relatively little effect on the growth or pancreatic endocrine function her foal after birth. 401 
However, there were treatment differences in placental area and femur length of the foal at 402 
birth. There are also differences in the pancreatic β cell response of the foals to arginine after 403 
maternal dexamethasone treatment, which became evident between 2 and 12 weeks. This 404 
indicates that dexamethasone treatment during pregnancy can have longer term metabolic 405 
consequences for the offspring in horses as occurs in other species [25-27]. Certainly, 406 
glucocorticoid overexposure of foals immediately after birth is known to have metabolic and 407 
endocrine effects long after weaning [41, 43]. Taken together, the current findings suggest 408 
that dexamethasone may have programming effects during equine pregnancy, possible due to 409 
maternal metabolic changes and placental growth restriction.  410 
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FIGURE LEGENDS 454 
Figure 1: Mean ±SEM increments in the plasma concentrations of (A) glucose and (B) 455 
insulin from basal 0 min values in response to glucose administration (at 0 min) pre-, during 456 
and post-treatment of pregnant mares with dexamethasone (filled symbols, n=6) or saline 457 
(open symbols, n=4-5). Details of the dosing regimen are given in the text. *Significant 458 
increment from basal value either for a specific sampling time and treatment group when 459 
given singly or for both groups when spanning a range of sampling times (t-test, P<0.05). 460 
 461 
Figure 2: Mean ±SEM values of the area under the response curve (AUC) for (A) glucose, 462 
AUCG, and (B) insulin, AUCI and (C) relative insulin secretion (AUCI:AUCG) in pregnant 463 
mares pre-, during and post-treatment with dexamethasone (filled columns, n=6) or saline 464 
(open columns, n=4-5). Details of the dosing regimen are given in the text. Within each 465 
treatment group, columns with different superscripts are significantly different from each 466 
other (one-way ANOVA, P<0.05). 467 
 468 
Figure 3: Mean ±SEM increments from basal 0min values in the plasma concentrations of 469 
(A) glucose and (B) insulin in response to glucose administration at 0 min and of (C) α-amino 470 
nitrogen and (D) insulin in response to arginine administration at 0 min in foals at 2 and 12 471 
weeks delivered by mares treated with dexamethasone (filled symbols, n=6) or saline (open 472 
symbols, n=4). *Significant increment from basal value either for a specific sampling time 473 
and treatment group when given singly or for both groups when spanning a range of sampling 474 
times (t test, P<0.05). † significantly different from value in the saline treatment group (two-475 
way ANOVA, P<0.05). # significantly different from values at 2 weeks in both treatment 476 
groups (two-way ANOVA, P<0.05). 477 
 478 
 479 
 480 
 481 
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Table 1:  Mean ± SEM basal concentrations of plasma glucose, L-lactate and insulin after an 612 
overnight fast and the maximum concentrations of glucose and insulin in response to glucose 613 
administration (0.25 g/kg) pre-treatment (-48 h from 1st dose), during treatment (+24 h after 614 
2nd dose) and post-treatment (+72 h after 3rd dose) of pregnant mares with 3 doses of 615 
dexamethasone (Dex, im, 200 µg/kg) or saline (im, 0.9%w/v) at 48 h intervals during late 616 
pregnancy.  617 
     Pre- 
  treatment 
  During  
  treatment 
   Post- 
   treatment 
      
Basal values Glucose mmol/l Saline   6.39 ± 0.91   5.53 ± 0.44     5.65 ± 0.41 
  Dex   6.98 ± 0.76a   7.24 ± 0.33a* 4.80 ± 0.04b* 
      
    L-Lactate mmol/l Saline    1.42 ± 0.30  1.50 ± 0.29    1.06 ± 0.08 
  Dex   1.41 ± 0.10a 2.58 ± 0.27b*  1.05 ± 0.13a 
      
 Insulin ng/ml Saline    340 ± 260      60 ± 20        56 ± 10 
  Dex    440 ± 160ab 1130 ± 250b*  201 ± 80a* 
      
Maximal 
values 
Glucose mmol/l Saline 19.18 ± 1.67 16.93 ± 0.89   20.55 ± 2.21 
  Dex 19.13 ± 1.18 20.63 ± 1.93   17.57 ± 0.57 
      
 Insulin ng/ml Saline     805 ± 315   860 ± 412       983 ± 441 
  Dex  1173 ± 278a 2542 ± 271b*   1178 ± 234a 
 618 
Values within rows with different superscripts are significantly different from each other 619 
(P<0.05, one-way ANOVA) * Significantly different from value in the saline treated group at 620 
the same time (P<0.05, t-test). 621 
 622 
 623 
 624 
 625 
 626 
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Table 2 : Mean ± SEM biometry measurements of the placenta at birth and of the foals at 
birth, 2 weeks and 12 weeks of postnatal age delivered by mares treated with 3 doses of 
saline (n=4-5) or dexamethasone (n=6, 200 µg/kg) at 48 h intervals during late pregnancy. 
 
   Treatment  
  
Measurement 
 
Age 
 
Saline 
 
Dexamethasone 
     
Placenta Weight (kg) Birth   2.27 ± 0.20  1.88 ± 0.20 
 Area (cm2) Birth   8290 ± 510  6870 ± 340* 
     
Foal Weight (kg) Birth 26.9 ± 2.0 21.6 ± 1.8 
  2 weeks 42.1 ± 5.0 34.2 ± 2.7 
  12 weeks  100.1 ± 7.4 85.4 ± 3.8 
     
 Crown rump length (cm) Birth 74.3 ± 2.6 68.3 ± 3.4 
  2 weeks 82.2 ± 3.7 74.7 ± 2.9 
  12 weeks  116.5 ± 2.2    109.8 ± 2.3 
     
 Height at wither (cm) Birth 80.7 ± 2.5 73.9 ± 2.3 
  2 weeks 86.3 ± 3.0 81.3 ± 2.2 
  12 weeks  103.4 ± 2.9 98.8 ± 1.5 
     
 Femur length (cm) Birth 25.7 ± 0.3  23.0 ± 0.7* 
  2 weeks 29.0 ± 1.8      27.0 ± 0.8 
  12 weeks 37.3 ± 1.3      35.0 ± 0.7 
 627 
*Significantly less than value in the saline treated group (P<0.02, t-test) 628 
 629 
 630 
 631 
 632 
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Table 3: Mean ± SEM vales of basal (fasted) and maximal concentrations of glucose, α-
amino nitrogen and insulin,  the area under of the curve (AUC) of the glucose,  α-amino 
nitrogen and insulin responses and the relative insulin secretion in  response to 
administration of glucose (0.5 g/kg) or arginine (100 mg/kg) in foals at 2 weeks and 12 
weeks of postnatal age delivered by mares treated with saline (n=4) or dexamethasone 
(Dex, n=6) during late pregnancy. 
   2 weeks 12 weeks 
    
Glucose administration    
Basal glucose mmol/l Saline    7.92 ± 0.29   6.78 ± 0.30 
  Dex   7.70 ± 0.36   6.88 ± 0.52 
Maximum glucose mmol/l Saline 21.08 ± 1.12   26.80 ± 1.67# 
  Dex 20.87 ± 1.11   24.67 ± 1.18# 
AUC glucose (AUCG) mmol/l/min Saline 268 ± 23     702 ± 104# 
  Dex 277 ± 21   599 ± 29# 
     
Basal insulin  ng/l Saline   194 ± 115     50 ± 10# 
  Dex  60 ± 20   27 ± 5# 
Maximum insulin ng/l Saline   730 ± 310 386 ± 52 
  Dex  470 ± 150 272 ± 62 
AUC insulin (AUCI) ng/l/min Saline     14309 ± 4150 24680 ± 5630 
  Dex    14425 ± 5855     17869 ± 4100 
     
Relative insulin secretion  AUCI: AUCG Saline           58 ± 22           38 ± 10 
  Dex           53 ± 21           30 ± 8 
     
Arginine administration    
     
Basal α-amino nitrogen mmol/l Saline        2.67 ± 0.13       2.16 ± 0.10# 
  Dex       2.40 ± 0.19       2.01 ± 0.11# 
Maximum α-amino nitrogen mmol/l Saline       3.18 ± 0.04       3.08 ± 0.24 
  Dex       3.33 ± 0.34       3.00 ± 0.21 
AUC α-amino nitrogen (AUCαAN) 
mmol/l/min 
Saline          21 ± 7          11 ± 2 
 Dex          24 ± 7          24 ± 2† 
    
Basal insulin ng/l Saline           63 ± 27 55 ± 11 
  Dex 96 ± 55 40 ± 14 
Maximum insulin ng/l Saline         247 ± 45        227 ± 17 
  Dex        265 ± 61        155 ± 31 
AUC insulin (AUCI) ng/l/min Saline 5195 ± 1608 7620 ± 1438 
  Dex 6622 ± 2456 5170 ± 1625 
     
Relative insulin secretion AUCI:AUCαAN Saline 538 ± 378 764 ± 161 
  Dex 873 ± 598 212 ± 54† 
 633 
# Significantly different from value in the same group at 2 weeks (P<0.01, t-test). 634 
†Significantly different from value in the saline treated group at the same age (P<0.05, t-test). 635 
 636 
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Figure 2 649 
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